Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)

Terry F Davies, MD, FRCP, FACE
Section Editor
Douglas S Ross, MD
Deputy Editor
Jean E Mulder, MD


The eye disease often associated with Graves' thyroid disease is referred to as Graves' ophthalmopathy. However, it is primarily a disease of the orbit and is better called Graves' orbitopathy. This topic review will provide an overview of the pathogenesis and clinical features of Graves' ophthalmopathy, which is an autoimmune disease of the retroorbital tissues. Treatment of this disorder is discussed separately. (See "Treatment of Graves' orbitopathy (ophthalmopathy)".)


The pathogenesis of Graves' ophthalmopathy is becoming more clearly understood. The volume of both the extraocular muscles and retroorbital connective and adipose tissue is increased, due to cellular proliferation, inflammation, and the accumulation of hydrophilic glycosaminoglycans (GAG), principally hyaluronic acid, in these tissues [1,2]. GAG secretion by fibroblasts is increased by thyroid-stimulating antibodies and activated T cell cytokines such as tumor necrosis factor (TNF) alpha and interferon gamma, implying that both B and T cell activation are important parts of this immunopathology. The accumulation of GAG causes a change in osmotic pressure, which in turn leads to a fluid accumulation, muscle swelling, and an increase in pressure within the orbit. These changes, together with retroorbital adipogenesis, displace the eyeball forward and can also interfere with the function of the extraocular muscles and the venous drainage of the orbits (figure 1 and image 1).

On histologic examination, the extraocular muscles are swollen, and some muscle fibers show loss of striation, fragmentation, and infiltration with lymphocytes, most of which are T lymphocytes (picture 1). The following observations suggest that these T cells may play a central role in the development of ophthalmopathy [3-5]:

In vitro studies of retroorbital tissue from patients with Graves' ophthalmopathy have shown that the infiltrating T cells are activated by retroorbital tissue fractions.

Retroorbital fibroblasts secrete GAG in response to cytokines such as interferon gamma and TNF alpha secreted by helper (CD4+) T cells of the Th1 type.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Dec 18, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362:726.
  2. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747.
  3. Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75:222.
  4. Wall JR, Salvi M, Bernard NF, et al. Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders. Immunol Today 1991; 12:150.
  5. Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994; 93:2738.
  6. Heufelder AE, Herterich S, Ernst G, et al. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995; 132:266.
  7. Davies TF. The thyrotropin receptors spread themselves around. J Clin Endocrinol Metab 1994; 79:1232.
  8. Kodama K, Sikorska H, Bandy-Dafoe P, et al. Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy. Lancet 1982; 2:1353.
  9. Bahn RS, Gorman CA, Johnson CM, Smith TJ. Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. J Clin Endocrinol Metab 1989; 69:622.
  10. Ross PV, Koenig RJ, Arscott P, et al. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab 1993; 77:433.
  11. Kendler DL, Davies TF. Immunological mechanisms in Graves' disease. In: Molecular Pathology of Autoimmunity, Bona C, Siminovitch K, Theofilopoulos AN, Zanetti M (Eds), Harwood Academic, New York 1993. p.511.
  12. Valyasevi RW, Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999; 84:2557.
  13. Villanueva R, Inzerillo AM, Tomer Y, et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000; 10:791.
  14. Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. Thyroid 1997; 7:3.
  15. Spitzweg C, Joba W, Hunt N, Heufelder AE. Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. Eur J Endocrinol 1997; 136:599.
  16. Moshkelgosha S, So PW, Deasy N, et al. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 2013; 154:3008.
  17. Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest 2002; 110:161.
  18. Bahn RS, Dutton CM, Joba W, Heufelder AE. Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid 1998; 8:193.
  19. Bahn RS. Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am 2000; 29:287.
  20. Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83:998.
  21. Bell A, Gagnon A, Grunder L, et al. Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol 2000; 279:C335.
  22. Huber GK, Weinstein SP, Graves PN, Davies TF. The positive regulation of human thyrotropin (TSH) receptor messenger ribonucleic acid by recombinant human TSH is at the intranuclear level. Endocrinology 1992; 130:2858.
  23. McGregor AM. Has the target autoantigen for Graves' ophthalmopathy been found? Lancet 1998; 352:595.
  24. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008; 181:4397.
  25. Marinò M, Lisi S, Pinchera A, et al. Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid 2001; 11:177.
  26. Davies TF. Graves' disease: Pathogenesis. In: Werner & Ingbar's The Thyroid, 8th, Braverman LE, Utiger RD (Eds), Lippincott, Williams & Wilkins, Philadelphia 2000. p.518.
  27. Morrison H. The familial incidence of exophthalmic goiter. N Engl J Med 1928; 199:85.
  28. Frecker M, Stenszky V, Balazs C, et al. Genetic factors in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1986; 25:479.
  29. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993; 38:367.
  30. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269:479.
  31. Szucs-Farkas Z, Toth J, Kollar J, et al. Volume changes in intra- and extraorbital compartments in patients with Graves' ophthalmopathy: effect of smoking. Thyroid 2005; 15:146.
  32. Costabel U, Bross KJ, Reuter C, et al. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986; 90:39.
  33. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92:59.
  34. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91:3464.
  35. Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbital involvement in Graves's disease. N Engl J Med 1974; 290:1447.
  36. Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80:2830.
  37. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995; 120:511.
  38. WERNER SC. Euthyroid patients with early eye signs of Graves' disease; their responses to L-triiodothyronine and thyrotropin. Am J Med 1955; 18:608.
  39. Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 1990; 70:89.
  40. Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:426.
  41. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326:1733.
  42. Wartofsky L. Classification of eye changes of Graves' disease. Thyroid 1992; 3:235.
  43. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001; 55:283.
  44. Martins JR, Furlanetto RP, Oliveira LM, et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2004; 60:726.
  45. Gerding MN, van der Zant FM, van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1999; 50:373.
  46. Moncayo R, Baldissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide. Thyroid 1997; 7:21.
  47. Ujhelyi B, Erdei A, Galuska L, et al. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. Thyroid 2009; 19:375.
  48. Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 1986; 7:651.
  49. Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy--stimulating antibodies. J Clin Endocrinol Metab 1998; 83:3777.